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Abstract
Background: Some patients with long-standing low back pain will benefit from treatment with
strong opioids. However, it would be helpful to predict which patients will have a good response.
A fixed-term opioid trial has been recommended, but there is little evidence to suggest how long
this trial should be. We assessed data from a large-scale randomized comparison of transdermal
fentanyl (TDF) and sustained-release oral morphine (slow-release morphine; SRM) to determine
characteristics of treatment responders.
Methods: This was a secondary analysis of a previously published 13-month randomized trial
involving 680 patients with long-standing low back pain (median age 52 years, 61% women, median
duration of back pain 87 months). Pain relief was recorded using visual analogue scales (VAS).
Treatment response was defined as pain relief of at least 30% from baseline to any point during the
trial. We used a step-wise logistic regression to identify variables that might predict response to
treatment. Covariates included treatment group, sex, age, duration of pain, presence of
neuropathic pain, baseline pain scores, educational/employment status, use of high doses of opioids,
and social functioning (SF)-36 scores.
Results: Over half the patients in both groups (n = 370; 54% TDF, 55% SRM) were treatment
responders. There were no differences between the TDF and SRM responders in terms of age, sex,
type or duration of pain between responders and non-responders. The difference in response to
treatment between responders and non-responders could be detected at 3 weeks. Lack of
response after 1 month had a stronger negative predictive value (i.e., ability to detect non-
responders) than the presence of response after 1 month. The most influential factors for
predicting a response were employment status (χ2 = 11.06, p = 0.0259) and use of high doses of
opioids (χ2 = 3.04, p = 0.0811).
Conclusion:  No clear pattern of baseline pain (type or severity) or patient characteristics
emerged that could be used to predict responders before the start of opioid treatment. However,
a 1-month trial period appears sufficient to determine response and tolerability in most cases.
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Background
Strong opioids are accepted as an option for patients with
long-standing low back pain, but not all patients respond
satisfactorily to this treatment. It would be helpful to be
able to predict which patients are most likely to have a
good, long-term response to strong opioid therapy to
avoid exposing patients to ineffective treatments or side-
effects. Even if it does not prove possible to identify good
responders before starting treatment, it would be useful to
know how long an opioid trial is required to determine
response. We have analyzed findings from a randomized,
controlled trial of transdermal fentanyl and sustained-
release oral morphine in strong-opioid naive patients
with chronic low back pain to gather information about
predicting response and about the inter-relationships
between analgesia and other effects of treatment.
Methods
The primary study (FEN-INT-26) has been published sep-
arately [1]. It included 680 patients with long-standing
low back pain who were randomized to treatment with
either slow-release morphine (SRM) or transdermal fenta-
nyl (TDF) for 13 months. Individuals who had received
regular treatment with a strong opioid (i.e. more than four
doses over a 7-day period) at any time during the 4 weeks
preceding the study were excluded.
Patients were excluded if they had conditions that were
likely to predispose them to ventilatory depression, intol-
erance to morphine or fentanyl (e.g. chest disease, renal
dysfunction), skin problems that might affect transdermal
delivery), a history of alcohol or substance abuse, or a life-
limiting condition.
Pain relief was assessed weekly using visual analogue
scales for pain relief (VAS) from patient diaries. There
were monthly assessments of pain (at rest, on movement,
during the day and at night). Adverse events were
recorded throughout the study. For the purpose of this
secondary analysis, treatment response was defined as
pain relief of at least 30% from baseline to any point dur-
ing the trial [2].
We performed a step-wise logistic regression to identify
variables that might predict response to treatment with
strong opioids during the trial. Covariates included in the
initial model were: randomization group (fentanyl or
morphine), sex, age, duration of pain, presence of neuro-
pathic pain, educational/employment status, use of high
doses of opioids (>100 μg/h TDF or >390 mg/day SRM)
during the trial, baseline scores for pain at rest, pain on
movement, and SF-36 scores (mental health, social func-
tioning and physical functioning). The selection of covari-
ates focused on those, which might have a possible effect
on treatment outcome based on published literature and
clinical experience [3-12]. We examined the effects of
these variables on the likelihood of patients experiencing
at least a 30% or 50% pain relief at several time points.
Responses at earlier time points (1 month) were analyzed
as predictors for response later on.
Patient characteristics
The median age was 52 years (range 20–89), 61% of the
680 participants were women. The median duration of
back pain was 87 months (range 2–768, mean 125
months); 51% of patients completed the study. Reasons
for withdrawal included adverse events (37% TDF, 31%
SRM) and insufficient response (5% TDF, 4% SRM).
Results
Responder analysis
Treatment response was defined as a pain relief of at least
30% (VAS scores) at any time point during the trial. Over
half the patients in both groups (n = 370; 54% for TDF,
55% for SRM) were classified as treatment responders.
There were no differences between the TDF and SRM
responders in age, sex, type of pain (nociceptive or neuro-
pathic) or duration of pain between responders and non-
responders. The physical functioning score of the SF-36
differed only slightly between responders (28, 3) and
non-responders (30, 1).
Of the participants who experienced at least a 30% pain
relief at any time during the trial, most (74% for TDF and
70% for SRM) also experienced at least a 50% reduction
in pain severity in one of the back pain categories. There
was no difference between the 50% responders and non-
responders in baseline characteristics.
The difference in response to treatment between respond-
ers and non-responders could be detected at 3 weeks. Both
groups had similar pain severity after 1 week, but by 3
weeks the non-responders had, on average, more pain
than at baseline, while the responders had less pain. This
suggests that an assessment period of 1 month may be suf-
ficient to determine responsiveness to a strong opioid.
The amount of patients suffering from moderate to severe
pain in any of the low back pain categories was lower in
the responder group at endpoint compared to the non-
responder group (Figure 1). There was however also a
small reduction of patients suffering from moderate to
severe pain in any of the low back pain categories in the
non-responder group compared to baseline.
The odds ratios for the likelihood of being classified as a
responder at 6 and 12 months (depending on whether
patients were responders at 1 month) are shown in Table
1. These indicate that a lack of response after 1 month has
a stronger negative predictive value (i.e. ability to detectBMC Medicine 2007, 5:39 http://www.biomedcentral.com/1741-7015/5/39
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non-responders) than the presence of response after 1
month. The predictive value for 50% pain relief was
slightly higher than for 30% pain relief (odds ratios 5.08
and 4.36, respectively), but both were significantly associ-
ated with response at 6 months (p < 0.0001 in both
cases). Response at 1 month was also associated with
response at 12 months, although the odds ratios were less
pronounced at this stage, probably due to the larger
number of missing cases (OR 3.17 (95% CI 1.77–5.68)
for 30% response and 3.47 (1.30–9.28) for 50%
response).
Treatment responders were more likely to complete the
study than non-responders (69% for 30% responders vs
28% for non-responders). The most common reason for
non-completion was an adverse event. On average, the
non-responders dropped out of the study significantly
earlier than the treatment responders (54 days vs 178 days
p < 0.001, Figure 2). The rate of dropout for non-respond-
ers appeared to be greatest during the first 2 months, after
which it reduced.
The dose pattern from 4 weeks to endpoint was broadly
similar for 30% responders and non-responders who
completed the study. The most common category of dose
change over this period was 75–100%; this was observed
in 32% of responders and 35% of non-responders who
completed the study. The proportion of patients whose
opioid dose more than doubled between 4 weeks and
study end (for those who completed the study) was iden-
tical for responders and non-responders (24% in both
groups).
Characteristics of non-responders
About half the participants were classified as treatment
responders (i.e. had at least a 30% pain relief VAS AUC
[Area under the curve]); over three-quarters of participants
(530/680 = 78%) experienced some improvement in
mental health, physical or social functioning (assessed by
the SF-36) or an improvement in one of the specific back
pain categories (at rest, during the day, at night, or on
movement). Patients who had no response in any aspect
tended to withdraw from the study after a short period
(median time to withdrawal was 15 days for non-
responders vs 99 days for others, mean 34 and 139 days,
respectively, p < 0.001). Only 10 (7%) of these non-
responders completed the study. The commonest reason
for withdrawal was an adverse event that occurred in 111/
136 (82%) of the dropouts.
The small group of non-responders who remained in the
study for more than 4 weeks (n = 37) tended to be on
higher opioid doses than other patients. The mean dose
(mg morphine or equivalents for fentanyl) at 5 weeks was
116 (95% CI 92, 139) mg for non-responders compared
with 94 (89, 98) mg for other participants. At 12 weeks,
the mean doses were 156 (95% CI 104, 207) mg and 114
(95% CI 107, 120) mg, respectively.
Some aspects of pain improved more than others with
strong-opioid treatment, e.g. the responders reporting
Treatment duration in responders and non-responders Figure 1
Treatment duration in responders and non-responders.
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Table 1: Relationship between pain relief at 1 month and at 6 months
Response at 1 month Response at 6 months n (%) Odds ratio (95% CI)
No Yes Missing
30% Response
No 188 (55) 49 (14) 105 4.36 (2.61–7.28)
Yes 44 (35) 50 (40) 30
50% Response
No 261 (62) 36 (9) 105 5.08 (2.36–10.93)
Yes 14 (29) 20 (42) 14BMC Medicine 2007, 5:39 http://www.biomedcentral.com/1741-7015/5/39
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Incidence and severity of (a) nausea, (b) constipation, (c) somnolence, (d) sweating, and (e) pruritus Figure 2
Incidence and severity of (a) nausea, (b) constipation, (c) somnolence, (d) sweating, and (e) pruritus. FEN, 
patients receiving transdermal fentanyl; SRM, patients receiving sustained release oral morphine. 1, incidence at day 1; 2–15, 
incidences at day 2, 3, etc. Numbers below x-axis show number of patients at each time point.
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severe pain on movement fell from 66% at baseline to
21% at endpoint.
Effects of age
Older patients (defined as those at least 75 years old, n =
51) tended to use lower opioid doses than younger
patients (<75 years, n = 621). The median daily doses at
study endpoint were 58 mg for SRM and 43 μg/h (102
mg) for TDF for older patients compared with 116 mg
SRM and 54 μg/h (130 mg) TDF for younger patients. The
average morphine dose in older patients remained stable
throughout the study; the mean morphine dose was 57
mg at baseline and 59 mg at endpoint, however the mean
dose in patients who completed the study was 66 mg at
month 13. The average fentanyl dose was 25 μg/h at base-
line, 44 μg/h at endpoint (for all patients, whenever they
left the study), and 50 μg/h at month 13 (i.e. for patients
who completed the study).
The proportion of responders tended to be higher in the
younger than the older age groups (56% vs 45%, respec-
tively, for 30% response and 40% vs 31%, respectively, for
50% response). However, no statistical significance could
be detected, probably due to the small sample size. The
proportion of patients who withdrew because of adverse
events was higher in the elderly sub-group than in the
younger patients: rates of withdrawal were 56% (n = 15)
for SRM and 42% (n = 10) for TDF in the older group
compared with 29% (n = 89) and 37% (n = 115), respec-
tively in the younger patients.
Adverse events
Most adverse events (AEs) were reported in the first few
weeks of the study, except for sweating in the fentanyl
group, which increased over time (Figure 3). To examine
whether patients who experienced AEs were more likely to
withdraw from the study before an effective dose had
been reached, we compared doses in patients with and
without the most common AEs.
The median daily opioid dose was lower for patients <75
years old who reported nausea than for those who did not
(76 mg morphine (n = 159) or 38 μg fentanyl (n = 170)
for patients with nausea vs 85 mg morphine (n = 151) or
48 μg fentanyl (n = 141) for those without). This pattern
was not seen for those who reported constipation
(median morphine dose of SRM patients <75 years was 84
mg for those with (n = 204) vs 72 mg for those without (n
= 106) constipation, (doses for fentanyl 48 μg (n = 163)
vs 38 μg (n = 148), respectively).
Evidence that vomiting may limit treatment comes from
the observation that patients who experienced at least a
30% pain relief were less likely to report this AE than non-
responders (23% of responders and 33% of non-respond-
ers reported vomiting). However responders were more
likely to report constipation than non-responders (67% vs
47%), perhaps reflecting the greater length of time they
remained in the study since constipation tends to occur
after several weeks of opioid treatment.
Dosage and study completion
Dose increases between 4 weeks and endpoint tended to
be larger in patients who completed the study than those
who dropped out. For example, the proportion of patients
whose opioid dose more than doubled during this time
was 24% for completers and 7% for non-completers.
Best and worst responders
Demographic and baseline characteristics of the best and
worst responders (top and bottom 15%) were compared.
The mean (±standard error of the mean (SEM)) duration
of chronic pain was no different in the poor responders
than in the best responders (106 ± 10 vs 94 ± 8 months).
No clear patterns emerged that might predict response,
except that there were significantly more women in the
SRM worst response group (73% of the poorest respond-
ers to morphine were female compared with 49% of the
poorest responders to fentanyl, p = 0.017).
Reasons for leaving study
Patients who left the study in the first month (i.e. early
drop-outs, n = 135 comprising 20% of the total popula-
tion) were compared with those who withdrew from the
study at a later stage (n = 199). Drop-outs within the first
month were more likely to be due to adverse events (82%
vs 59%) and less likely to be due to insufficient response
(3% vs 15%) than with later withdrawals. The proportion
Proportion of patients with moderate/severe pain at baseline  and endpoint by response category Figure 3
Proportion of patients with moderate/severe pain at baseline 
and endpoint by response category.
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of patients withdrawing consent was 9% among early
dropouts and 6% among later withdrawals.
Adverse events during the first month were compared
between early dropouts and all patients who remained in
the study for longer (n = 540). Nausea and vomiting were
more common in early dropouts (62% vs 43% for nausea,
and 38% vs 20% for vomiting, respectively). Constipation
and increased sweating were less frequent among early
dropouts (36% vs 49% for constipation, and 8% vs 14%
for sweating). Pruritus was similar in early dropouts and
other patients (12% and 17%, respectively).
Effects of dose
The effect of opioid dose was assessed by considering the
sub-group of patients who received higher doses (>100
μg/h TDF or >390 mg/day SRM, n = 43). The incidence of
adverse events was similar in both dosage groups, except
for sweating, which occurred more often in the higher
dose group (35% higher dose vs 20% lower dose, p =
0.0207). The proportion of patients achieving at least
30% pain relief was higher in the higher dose group (70%
vs 54%, p = 0.043). A similar pattern was observed for the
proportions achieving at least 50% pain relief, but the dif-
ference between dose groups (44% vs 39%) did not reach
statistical significance when both treatments were consid-
ered together. There was a marked difference in the pro-
portion of patients achieving at least 50% pain relief in
the higher dose sub-group between those receiving TDF
(52% responders) and those receiving SRM (29%). This
difference was not observed in the lower dose group (39%
responders in each treatment group).
Multivariate analysis
We performed a step-wise logistic regression using 13 key
variables (Table 2). No strong correlation between any
covariates was found. The most influential factors for pre-
dicting a response of at least a 30% reduction of pain from
baseline were employment status (χ2 = 11.06, p = 0.0259)
and use of high doses of opioids (χ2 = 3.04, p = 0.0811).
The category 'non-professional' employment status,
which included housewives but not unemployed, retired
people or students, was associated with a lower likelihood
of achieving a 30% response than the 'disabled' category
(odds ratio compared with disabled category 0.412 (95%
CI 0.24 to 0.70) p = 0.0010). The use of higher opioid
doses during the trial gave an increased likelihood of
achieving a 30% response. This effect was statistically sig-
nificant (p = 0.049) in the first model, which included all
covariates, but fell below statistical significance in the
final model (p = 0.081, odds ratio 1.828 (95% CI 0.93 to
3.60)).
Variables predicting at least a 50% reduction in pain were
similar, and employment status (and the non-profes-
sional category) was one of the most influential factors,
however its contribution was not statistically significant
(p = 0.127). The strongest predictor for 50% response was
the presence of neuropathic pain, which was weakly pre-
dictive of poorer response (p = 0.0276). The odds ratio for
Table 2: Logistic regression on the probability of 30% responseNegative values indicate reduced probability of 30% response.
Variable (baseline value) Effect estimate p Value of Type 
III effect
Category (p value) Odds ratio 95% CI
Age -0.0007 0.9350 0.999 0.98–1.02
Mental health 0.0045 0.2935 1.004 1.00–1.01
Pain at rest -0.3612 0.1779 Moderate1 (0.0633) 0.697 0.48–1.02
Compared with no/slight pain -0.2503 Severe1 (0.2783) 0.779 0.50–1.22
Pain on movement -0.1683 0.6717 Moderate2 (0.6788) 0.845 0.38–1.87
Compared with no/slight pain -0.2926 Severe2 (0.4652) 0.746 0.34–1.64
Physical functioning (SF-36) -0.0055 0.2270 0.995 0.99–1.00
Social functioning (SF-36) -0.0036 0.3129 0.996 0.99–1.00
Duration of pain -0.0006 0.4152 0.999 0.99–1.00
Education -0.2680 0.5083 Apprenticeship3 (0.3462) 0.765 0.44–1.34
Compared with primary 
education
0.0649 Secondary education3 (0.7356) 1.07 0.73–1.56
0.2464 Higher education3 (0.4168) 1.28 0.71–2.32
Employment -0.1039 0.0582 Employed4 (0.6751) 0.901 0.55–1.47
Categories compared with 
disabled
-0.8852 Non-professional4 (0.0029) 0.413 0.23–0.74
-0.2908 Retired4 (0.2201) 0.748 0.47–1.19
-0.2739 Student4 (0.4163) 0.760 0.39–1.47
High dose 0.7185 0.0499 2.051 1.00–4.21
Neuropathic pain -0.1857 0.2735 0.831 0.60–1.16
Treatment group 0.0530 0.7434 1.054 0.77–1.45
Sex 0.0439 0.8033 1.045 0.74–1.48BMC Medicine 2007, 5:39 http://www.biomedcentral.com/1741-7015/5/39
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the presence of neuropathic pain on the likelihood of
50% response was 0.695 (95% CI 0.50 to 0.96).
Discussion
By 1 month, 20% of patients had stopped treatment, and
four out of five stopped treatment because of adverse
events. However, 54% of patients had at least 30% pain
relief during one time point of the trial and 69% of these
patients were still on opioid treatment after 12 months,
the dosages used by responders did not differ from those
used by non-responders.
This study provided an opportunity to investigate predic-
tive factors for response and gives important information
regarding the efficacy and natural course of adverse effects
over 13 months. However, this study was not originally
designed to test predictors and therefore many potentially
important factors were not examined (e.g. motivation and
expectations of the patient and the physician, and the
impact of other medications). As the study included only
carefully selected patients with a long history of chronic
low back pain, the findings need to be verified in a
broader population.
No clear pattern of baseline pain (type or severity) or
patient characteristics (e.g. age, gender) emerged that
could be used to predict responders before the start of opi-
oid treatment. However, this analysis did suggest that a 1-
month trial period is sufficient to determine response and
tolerability in most cases. The significant relationship
between response at 1 month and response after 6 and 12
months suggests that if patients have not responded to a
suitable dose of strong opioid after 1 month, then treat-
ment should be stopped and alternative pain relief intro-
duced. However, if patients experience at least a 30%
reduction in pain at 1 month, then opioid treatment
should be continued, as long-term benefit is more likely.
Previous studies have also found an association between
response to intravenous opioids and long-term treatment
[13]. As in the present study, Dellemijn et al. found that
not all patients responding to a single dose of an intrave-
nous opioid responded as well to long-term treatment.
The negative predictive power was stronger, and those
who did not respond to the intravenous opioid were less
likely to respond to long-term transdermal treatment.
Our findings can be expressed in terms of the sensitivity
and specificity of response at 1 month to predict response
at 6 months. Specificity is the probability of a response at
1 month and 6 months (i.e. the true positive rate) and is
calculated to be 0.505. Sensitivity is the probability of no
response at 1 month for those with no response at 6
months (i.e. the true negative rate) and is calculated to be
0.810. Thus lack of response at 1 month has stronger neg-
ative predictive power than the positive predictive power
of the presence of response at 1 month.
We noted that there were significantly more women in the
SRM worst response group than in the equivalent group
for TDF (73% vs 49%). Whether this is an indicator of sex
specific differences in response to opioid treatment needs
further investigation.
This large dataset allowed us to examine correlations
between the main outcome of the original study (pain
relief expressed by a decrease in VAS pain scores) and
other measurements of pain. We found a statistically sig-
nificant correlation between the pain relief score and the
change in back pain category (mild, moderate or severe)
from baseline to study endpoint.
Gastrointestinal side effects are relatively common in
patients receiving strong opioids for the first time. Nausea
and vomiting appear to limit treatment in some cases, and
may prevent titration to effective doses. Constipation
tends to emerge after a few weeks of treatment, and
occurred more frequently in patients receiving morphine
than in those receiving transdermal fentanyl. The median
daily opioid dose was lower in patients who reported nau-
sea than in those who did not but this pattern was not
seen for constipation. This suggests that the occurrence of
nausea during the early weeks of treatment may limit dose
titration, whereas constipation generally emerges later.
The higher median dose of TDF in patients who reported
constipation compared with those that did not might also
reflect a dose-response effect, with constipation occurring
only with higher doses of TDF.
The rate of adverse effect reporting is affected by the
reporting method. In our study, only adverse events vol-
unteered by patients (or observed by clinicians) were
reported, whereas, in other studies, patients have been
questioned specifically about the occurrence of expected
side effects. This may explain why the rates of adverse
events in our study are lower than those in some previous
studies of strong opioids [14]. However the adverse events
in this trial were analyzed with care.
Patients aged over 75 years in the SRM group showed sta-
ble doses throughout the study, in contrast to older
patients receiving TDF and to the younger patients in both
groups. Older patients in the SRM group reported less
pain relief than younger patients; this might also suggest
that effective morphine doses were not reached. One pos-
sible explanation for this is that older patients are more
susceptible to dose-related morphine side effects and this
limited dose escalation. This assumption is supported by
the higher dropout rate in the older patient group (56% in
the TDF and 42% in the SRM group). Other studies havePublish with BioMed Central    and   every 
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also noted that morphine side effects may be more pro-
nounced in elderly patients [15].
Only a small proportion of patients needed high opioid
doses, but these patients tended to achieve additional
pain relief.
Patients who experienced effective pain relief (e.g. a
decrease of at least 30% from baseline) tended to remain
in the trial longer than those who did not get adequate
analgesia. Some patients may have remained in the trial
because of other benefits apart from the primary outcome,
such as sleeping better. A few patients, who according to
trial assessments had experienced no benefits, still com-
pleted the 13-month trial.
Conclusion
Strong opioid treatment can be beneficial for some
patients with severe low back pain. However, there
appears to be no simple method of predicting who will
benefit from a strong opioid before treatment is initiated.
This analysis suggests that response to a trial period of 1
month gives a good indication of who will obtain sus-
tained benefit. Neuropathic pain does not appear to rule
out response to strong opioids, but it may be associated
with a poorer response. Gastrointestinal side effects are
common during the first weeks of treatment, and these
may limit dose titration in some patients. The best way to
determine who will tolerate a strong opioid appears to be
a trial period of 1 month.
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